{"id":60172,"date":"2024-10-15T13:04:21","date_gmt":"2024-10-15T11:04:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/"},"modified":"2024-10-15T13:04:21","modified_gmt":"2024-10-15T11:04:21","slug":"innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/","title":{"rendered":"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024"},"content":{"rendered":"<div>\n<p>WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finnovivaspecialtytherapeutics.com%2F&amp;esheet=54134608&amp;newsitemid=20241015096772&amp;lan=en-US&amp;anchor=Innoviva+Specialty+Therapeutics%2C+Inc.&amp;index=1&amp;md5=f0a19bc0fcbcc3593c42f84e09833b2f\" rel=\"nofollow noopener\" shape=\"rect\">Innoviva Specialty Therapeutics, Inc.<\/a>, a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the presentation of data from three clinical abstracts and two oral presentations on the company\u2019s pipeline and Commercial portfolio during <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fidweek.org%2F&amp;esheet=54134608&amp;newsitemid=20241015096772&amp;lan=en-US&amp;anchor=IDWeek+2024&amp;index=2&amp;md5=68511da881761d125a02ec5103ef38c6\" rel=\"nofollow noopener\" shape=\"rect\">IDWeek 2024<\/a>, October 16-19, 2024, in Los Angeles, CA.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/5\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/22\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/5\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/21\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\"><\/a><\/p>\n<p>\n\u201c<!-- no quote -->Our clinical program continues to provide important findings from recent sub-analyses that add meaningful new insights for healthcare professionals managing difficult-to-treat and antimicrobial-resistant pathogens,&#8221; said David Altarac, MD, Chief Medical Officer at Innoviva Specialty Therapeutics. &#8220;<!-- no quote -->We are pleased with the progress of our development product zoliflodacin, which recently completed the pivotal phase 3 trial conducted with our partner the Global Antibiotics Research Development Partnership. If approved, zoliflodacin could lead to the first new oral antibiotic to treat gonorrhea in decades.&#8221;\n<\/p>\n<p>\n<b>IDWeek 2024 Clinical Presentations<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Oral Presentation<br \/>\n<br \/><\/b><i>Addressing a growing global threat through a novel public-private development partnership<br \/>\n<br \/><\/i>David Altarac, MD, Chief Medical Officer, Innoviva Specialty Therapeutics<br \/>\n<br \/>Friday, October 18, 2024<br \/>\n<br \/>8:00 am \u2013 9:00 am PT<br \/>\n<br \/>Petree C<br \/>\n\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Oral Presentation<br \/>\n<br \/><\/b><i>Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023 \u2013 2024)<br \/>\n<br \/><\/i>Tomefa E. Asempa, PharmD, Hartford Hospital<br \/>\n<br \/>Saturday, October 19, 2024<br \/>\n<br \/>10:54-11:06 am PT<br \/>\n<br \/>Room 403A<br \/>\n\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Poster #P-1103<br \/>\n<br \/><\/b><i>In Vitro Activity of Zoliflodacin Against Baseline Neisseria gonorrhoeae Isolates from US Participants in a Global Phase 3 Randomized Controlled Trial<br \/>\n<br \/><\/i>Sarah McLeod, PhD, Innoviva Specialty Therapeutics<br \/>\n<br \/>Friday, October 18, 2024<br \/>\n<br \/>12:15-1:30 pm PT, Hall J&amp;K<br \/>\n\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Poster #P-1251<br \/>\n<br \/><\/b><i>Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated Gonorrhea<br \/>\n<br \/><\/i>Sujata M. Bhavnani, MD, Institute for Clinical Pharmacodynamics<br \/>\n<br \/>Friday, October 18, 2024<br \/>\n<br \/>12:15-1:30 pm PT, Hall J&amp;K Time<br \/>\n\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Poster# P-1532<br \/>\n<br \/><\/b><i>Surveillance of Eravacycline Against CLINICAL Pathogens, including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2018-2022<br \/>\n<br \/><\/i>Kristie Zappas, PharmD, Innoviva Specialty Therapeutics<br \/>\n<br \/>Friday, October 18, 2024<br \/>\n<br \/>12:15-1:30 pm PT, Halls JK\n<\/li>\n<\/ul>\n<p>\n<b>About Innoviva Specialty Therapeutics<\/b>\n<\/p>\n<p>\nInnoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics\u2019 products, through its affiliate, La Jolla Pharmaceutical Company, include GIAPREZA<sup>\u00ae<\/sup> (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA<sup>\u00ae<\/sup> (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva Specialty Therapeutics\u2019 product, through its affiliate, Entasis Therapeutics Inc., include XACDURO<sup>\u00ae<\/sup> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of <i>Acinetobacter baumannii-calcoaceticus <\/i>complex<i> <\/i>(<i>Acinetobacter<\/i>). For more information about Innoviva Specialty Therapeutics, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innovivaspecialtytherapeutics.com%2F&amp;esheet=54134608&amp;newsitemid=20241015096772&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=94035ed0f4045efca9499b90eb807d73\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact<\/b>:<br \/>\n<br \/>David Patti<br \/>\n<br \/>Innoviva Corporate Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x44;&#97;&#x76;&#105;&#x64;&#46;&#x70;a&#x74;t&#x69;&#64;&#x69;n&#x76;a&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x44;&#x61;&#118;&#105;d&#x2e;&#x70;&#x61;&#116;ti&#x40;&#x69;&#110;&#118;a&#x2e;&#x63;&#x6f;&#109;<\/a><br \/>908.421.5971\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the presentation of data from three clinical abstracts and two oral presentations on the company\u2019s pipeline and Commercial portfolio during IDWeek 2024, October 16-19, 2024, in Los Angeles, CA. \u201cOur clinical program continues &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60172","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the presentation of data from three clinical abstracts and two oral presentations on the company\u2019s pipeline and Commercial portfolio during IDWeek 2024, October 16-19, 2024, in Los Angeles, CA. \u201cOur clinical program continues ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T11:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/22\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024\",\"datePublished\":\"2024-10-15T11:04:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/\"},\"wordCount\":456,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241015096772\\\/en\\\/2269562\\\/22\\\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/\",\"name\":\"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241015096772\\\/en\\\/2269562\\\/22\\\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\",\"datePublished\":\"2024-10-15T11:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241015096772\\\/en\\\/2269562\\\/22\\\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241015096772\\\/en\\\/2269562\\\/22\\\/innoviva_specialty_therapeutics_TM_primary_navy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/","og_locale":"en_US","og_type":"article","og_title":"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024 - Pharma Trend","og_description":"WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the presentation of data from three clinical abstracts and two oral presentations on the company\u2019s pipeline and Commercial portfolio during IDWeek 2024, October 16-19, 2024, in Los Angeles, CA. \u201cOur clinical program continues ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/","og_site_name":"Pharma Trend","article_published_time":"2024-10-15T11:04:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/22\/innoviva_specialty_therapeutics_TM_primary_navy.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024","datePublished":"2024-10-15T11:04:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/"},"wordCount":456,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/22\/innoviva_specialty_therapeutics_TM_primary_navy.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/","url":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/","name":"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/22\/innoviva_specialty_therapeutics_TM_primary_navy.jpg","datePublished":"2024-10-15T11:04:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/22\/innoviva_specialty_therapeutics_TM_primary_navy.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241015096772\/en\/2269562\/22\/innoviva_specialty_therapeutics_TM_primary_navy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60172"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60172\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}